Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies

Approximately 50% of human malignancies carry p53 mutations, which makes it a potential antigenic target for cancer immunotherapy. Adoptive transfer with p53-specific cytotoxic T-lymphocytes (CTL) and CD4(+) T-helper cells eradicates p53-overexpressing tumors in mice. Furthermore, p53 antibodies and...

Descripción completa

Detalles Bibliográficos
Autores principales: Vermeij, R., Leffers, N., van der Burg, S. H., Melief, C. J., Daemen, T., Nijman, H. W.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085500/
https://www.ncbi.nlm.nih.gov/pubmed/21541192
http://dx.doi.org/10.1155/2011/702146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3085500/
https://www.ncbi.nlm.nih.gov/pubmed/21541192
http://dx.doi.org/10.1155/2011/702146

Ejemplares similares